SEC Company Response from StemGen, Inc. (CIK 0001023198) — Jul 14, 2020
StemGen, Inc. (CIK 0001023198)
Date: July 14, 2020 · CIK: 0001023198 · Accession: 0001161697-20-000314
AI Filing Summary & Sentiment
File numbers found in text: 333-235837
Referenced dates: July 6, 2020
Letter
Division of Corporation Finance Office of Technology Re: StemGen, Inc. Amendment No. 2 to Registration Statement on Form S-1 Filed June 23, 2020 File No. 333-235837
Dear Mr. Crispino:
This letter is in response to your letter of comment dated July 6, 2020 covering the captioned Amendment No. 2 to Registration Statement filed with the Commission on June 23, 2020. For your convenience, we will restate your comments followed by our responses.
Cover Page
1. We note your response to prior comment 1. You continue to indicate on the cover page and in the Plan of Distribution section that selling stockholders may sell shares of your common stock at varying prices. Please revise your cover page and Plan of Distribution to disclose the fixed price at which shares of your common stock will be sold until your shares are listed on a national securities exchange or quoted on the OTC Bulletin Board, OTCQX or OTCQB. Please also clarify on the cover sheet that the common stock is quoted on the OTC Pink.
The cover page and Plan of Distribution section has been revised in response to your comment.
Yours very truly,
Robert L. Sonfield, Jr.
Managing Director
cc: Simon Dawson (via e-mail)
Show Raw Text
CORRESP
1
filename1.htm
S O N F I E L D & S O N F I E L D
A Professional Corporation
LEON SONFIELD (1865-1934)
GEORGE M. SONFIELD (1899-1967)
ROBERT L. SONFIELD (1893-1972)
FRANKLIN D. ROOSEVELT, JR. (1914-1988)
ATTORNEYS
AT LAW
2500 WILCREST DRIVE,
3RD FLOOR
HOUSTON, TEXAS
77042-2754
WWW.SONFIELD.COM
TELECOPIER (713) 877-1547
____
TELEPHONE (713)
877-8333
ROBERT L. SONFIELD, JR.
Managing Director
robert@sonfield.com
Jennifer Abney
Legal Assistant
jennifer@sonfield.com
July 9, 2020
By EDGAR correspondence
Mr. Matthew Crispino
Division of Corporation Finance
Office of Technology
U.S. Securities and Exchange Commission
Washington, D.C. 20549
Re:
StemGen, Inc.
Amendment No. 2 to Registration Statement on Form S-1
Filed June 23, 2020
File No. 333-235837
Dear Mr. Crispino:
This letter is in response to your letter of comment dated July
6, 2020 covering the captioned Amendment No. 2 to Registration Statement filed with the Commission on June 23, 2020. For your convenience,
we will restate your comments followed by our responses.
Cover Page
1.
We note your response to prior comment 1. You
continue to indicate on the cover page and in the Plan of Distribution section that selling stockholders may sell shares of
your common stock at varying prices. Please revise your cover page and Plan of Distribution to disclose the fixed price at
which shares of your common stock will be sold until your shares are listed on a national securities exchange or quoted on
the OTC Bulletin Board, OTCQX or OTCQB. Please also clarify on the cover sheet that the common stock is quoted on the OTC
Pink.
The cover page and Plan of Distribution section has been revised
in response to your comment.
Yours very truly,
Robert L. Sonfield, Jr.
Managing Director
cc: Simon Dawson (via e-mail)